Comparative Pharmacology
Head-to-head clinical analysis: ENTECAVIR versus VIDEX EC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTECAVIR versus VIDEX EC.
ENTECAVIR vs VIDEX EC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Entecavir is a guanosine nucleoside analogue with activity against hepatitis B virus (HBV) polymerase. It is phosphorylated intracellularly to the active triphosphate form, which competes with the natural substrate deoxyguanosine triphosphate and inhibits HBV polymerase (reverse transcriptase) activity, resulting in inhibition of viral DNA synthesis.
Nucleoside reverse transcriptase inhibitor (NRTI); intracellularly phosphorylated to active metabolite didanosine triphosphate, which inhibits HIV reverse transcriptase by competing with natural deoxynucleotides and causing DNA chain termination.
0.5 mg orally once daily; for lamivudine-refractory or decompensated liver disease: 1 mg orally once daily.
400 mg orally once daily on an empty stomach.
None Documented
None Documented
Clinical Note
moderateEntecavir + Ribavirin
"Entecavir may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateGanciclovir + Entecavir
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Entecavir."
Clinical Note
moderateValganciclovir + Entecavir
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Entecavir."
Terminal elimination half-life is approximately 128-149 hours (5-6 days) in patients with normal renal function; prolonged in renal impairment (up to 40 hours in severe impairment), necessitating dose adjustment based on creatinine clearance.
0.6–1.5 hours (short terminal half-life due to rapid intracellular phosphorylation and cellular retention of active triphosphate; clinical dosing accounts for intracellular half-life of ~12–15 hours)
Renal excretion of unchanged drug accounts for 60-73% of the dose; biliary/fecal elimination accounts for 27-40% via active tubular secretion and glomerular filtration.
Renal: >50% unchanged via glomerular filtration and tubular secretion; minimal biliary/fecal excretion (<2%)
Category A/B
Category C
Nucleoside Reverse Transcriptase Inhibitor
Nucleoside Reverse Transcriptase Inhibitor